The prognostic significance of Lung Immune Prognostic Index (LIPI) and Pan-immune-inflammation value (PIV) in patients with large cell neuroendocrine carcinoma

Abstract

Abstract Large cell neuroendocrine carcinomas (LCNEC) are rare tumors of the lung. Due to their rarity, there is no standard follow-up and treatment. Inflammation and immune systems play an important role in the pathogenesis, development, and progression of lung and other cancers. Lung Immune Prognostic Index (LIPI) and Pan-immune-inflammation value (PIV) are markers of inflammation and immune marker, and there is no study with LCNEC. Therefore, in our study to evaluate the relationship between these markers and LCNEC prognosis; We retrospectively analyzed 109 patients diagnosed with metastatic LCNEC in our center between 2009 and 2022 by calculating the LIPI and PIV values at the time of diagnosis. Median OS was 7.8 (95% Confidence interval (CI), 6.20-9.39) months. Respectively median OS times were 9.6 (95% CI, 7.28-11.91) months versus 4.5 (95% CI, 2.87-6.13) months in low and high LIPI scores. Median OS times were 10.25 months (95 CI, 9.12-11.32) compared to 3.95 months (95 CI, 2.5-6.36) in low and high PIV, respectively. In multivariate analysis ECOG performance score ( p=0.005), metastasis time (de novo vs recurrent) (p=0.008), platelet (p=0.04), albumin (p=0.026), lymphocyte count (p =0.037), LIPI (p =0.002) score and PIV (p =0.001) were related with survival time. In conclusion LIPI, PIV, ECOG performance score, de novo metastases, albumin levels, lymphocyte and platelet counts are associated with prognosis. These factors can be used in patient monitoring and treatment as simple and inexpensive biomarkers.